Clinical Characteristics and Choices Regarding Risk-Reducing Surgery in BRCA Mutation Carriers

被引:16
作者
Stuckey, Ashley [1 ,2 ,3 ]
Dizon, Don [1 ,2 ,3 ,5 ]
Wilbur, Jennifer Scalia [1 ,2 ]
Kent, Jessica [1 ,2 ]
Tejada-Berges, Trevor [1 ,2 ,3 ]
Gass, Jennifer [1 ,2 ,3 ,4 ]
Legare, Robert [1 ,2 ,3 ,5 ]
机构
[1] Brown Univ, Warren Alpert Med Sch, Breast Hlth Ctr, Program Womens Oncol,Women & Infants Hosp, Providence, RI 02905 USA
[2] Brown Univ, Warren Alpert Med Sch, Canc Risk & Prevent Program, Women & Infants Hosp, Providence, RI 02905 USA
[3] Brown Univ, Warren Alpert Med Sch, Women & Infants Hosp, Dept Obstet Gynecol, Providence, RI 02905 USA
[4] Brown Univ, Warren Alpert Med Sch, Women & Infants Hosp, Dept Surg, Providence, RI 02905 USA
[5] Brown Univ, Warren Alpert Med Sch, Women & Infants Hosp, Dept Med, Providence, RI 02905 USA
关键词
BRCA mutation; Breast cancer; Ovarian cancer; Prophylactic mastectomy; Salpingo-oophorectomy; OVARIAN-CANCER; BREAST; WOMEN; OOPHORECTOMY; FAMILIES;
D O I
10.1159/000276573
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Background/Aims: BRCA mutation carriers have a high lifetime risk of developing breast and ovarian malignancies. As genetic testing becomes widely available, preventative measures are a choice. We evaluated the characteristics of BRCA mutation carriers who chose prophylactic surgery (PS) compared to those who opted for surveillance. Methods: A retrospective chart review of patients with a mutation in the BRCA1 or BRCA2 genes was performed. Results: Ninety women were included, of whom 46 (51%) underwent PS. They were more likely to be a BRCA2 mutation carrier, parous, married, employed, and had a prior history of breast cancer. PS included 39 bilateral salpingo-oophorectomies and 13 mastectomies. Pathology was typically benign; however, 15% showed ductal carcinoma in situ of the breast, 8% reported infiltrating ductal carcinoma of the breast, 3% was adenocarcinoma of the fallopian tube, and 3% was adenocarcinoma of the ovary. Conclusion: It is notable that BRCA1 mutation carriers were less inclined to elect for PS. Evaluating the reasons for pursuing PS among women with a BRCA mutation is necessary and will require a larger data set. Longterm follow-up is required to describe the potential side effects of PS on quality of life. Copyright (C) 2010 S. Karger AG, Basel
引用
收藏
页码:270 / 273
页数:4
相关论文
共 9 条
[1]  
EASTON DF, 1995, AM J HUM GENET, V56, P265
[2]   Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families [J].
Ford, D ;
Easton, DF ;
Stratton, M ;
Narod, S ;
Goldgar, D ;
Devilee, P ;
Bishop, DT ;
Weber, B ;
Lenoir, G ;
Chang-Claude, J ;
Sobol, H ;
Teare, MD ;
Struewing, J ;
Arason, A ;
Scherneck, S ;
Peto, J ;
Rebbeck, TR ;
Tonin, P ;
Neuhausen, S ;
Barkardottir, R ;
Eyfjord, J ;
Lynch, H ;
Ponder, BAJ ;
Gayther, SA ;
Birch, JM ;
Lindblom, A ;
Stoppa-Lyonnet, D ;
Bignon, Y ;
Borg, A ;
Hamann, U ;
Haites, N ;
Scott, RJ ;
Maugard, CM ;
Vasen, H .
AMERICAN JOURNAL OF HUMAN GENETICS, 1998, 62 (03) :676-689
[3]   RISKS OF CANCER IN BRCA1-MUTATION CARRIERS [J].
FORD, D ;
EASTON, DF ;
BISHOP, DT ;
NAROD, SA ;
GOLDGAR, DE ;
HAITES, N ;
MILNER, B ;
ALLAN, L ;
PONDER, BAJ ;
PETO, J ;
SMITH, S ;
STRATTON, M ;
LENOIR, GM ;
FEUNTEUN, J ;
LYNCH, H ;
ARASON, A ;
BARKARDOTTIR, R ;
EGILSSON, V ;
BLACK, DM ;
KELSELL, D ;
SPURR, N ;
DEVILEE, P ;
CORNELISSE, CJ ;
VARSEN, H ;
BIRCH, JM ;
SKOLNICK, M ;
SANTIBANEZKOREF, MS ;
TEARE, D ;
STEEL, M ;
PORTER, D ;
COHEN, BB ;
CAROTHERS, A ;
SMYTH, E ;
WEBER, B ;
NEWBOLD, B ;
BOEHNKE, M ;
COLLINS, FS ;
CANNONALBRIGHT, LA ;
GOLDGAR, D .
LANCET, 1994, 343 (8899) :692-695
[4]   Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer [J].
Madalinska, JB ;
Hollenstein, J ;
Bleiker, E ;
van Beurden, M ;
Valdimarsdottir, HB ;
Massuger, LF ;
Gaarenstroom, KN ;
Mourits, MJE ;
Verheijen, RHM ;
van Dorst, EBL ;
van der Putten, H ;
van der Velden, K ;
Boonstra, H ;
Aaronson, NK .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (28) :6890-6898
[5]   Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation [J].
Meijers-Heijboer, H ;
Brekelmans, CTM ;
Menke-Pluymers, M ;
Seynaeve, C ;
Baalbergen, A ;
Burger, C ;
Crepin, E ;
van den Ouweland, AWM ;
van Geel, B ;
Klijn, JGM .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (09) :1675-1681
[6]   Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients [J].
Schwartz, MD ;
Lerman, C ;
Brogan, B ;
Peshkin, BN ;
Halbert, CH ;
DeMarco, T ;
Lawrence, W ;
Main, D ;
Finch, C ;
Magnant, C ;
Pennanen, M ;
Tsangaris, T ;
Willey, S ;
Isaacs, C .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (10) :1823-1829
[7]   The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews [J].
Struewing, JP ;
Hartge, P ;
Wacholder, S ;
Baker, SM ;
Berlin, M ;
McAdams, M ;
Timmerman, MM ;
Brody, LC ;
Tucker, MA .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (20) :1401-1408
[8]   Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing -: A single-institution study [J].
Uyei, Anne ;
Peterson, Susan K. ;
Erlichman, Julie ;
Broglio, Kristine ;
Yekell, Sandra ;
Schmeler, Kathkeen ;
Lu, Karen ;
Meric-Bernstam, Funda ;
Amos, Chris ;
Strong, Louise ;
Arun, Banu .
CANCER, 2006, 107 (12) :2745-2751
[9]   Effect of genetic cancer risk assessment on surgical decisions at breast cancer diagnosis [J].
Weitzel, JN ;
McCaffrey, SM ;
Nedelcu, R ;
MacDonald, DJ ;
Blazer, KR ;
Cullinane, CA .
ARCHIVES OF SURGERY, 2003, 138 (12) :1323-1328